Navigation Links
Sanofi-Aventis Recognized for Workplace Efforts to Prevent Cancer
Date:8/5/2009

BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received CEO Cancer Gold Standard(TM) accreditation from the non-profit organization CEO Roundtable on Cancer, in recognition of the company's extensive efforts to encourage employees at all U.S. facilities (sanofi-aventis U.S. and sanofi pasteur) to take an active role in their health and reduce their risks of developing cancer. The CEO Cancer Gold Standard is awarded to companies that have met exceptionally high standards of cancer prevention, screening and care in the workplace through concrete action in five defined areas. With this accreditation, sanofi-aventis becomes the 34th company to be granted this honor since the program's inception in 2006.

"We are proud to be recognized by the CEO Roundtable on Cancer for our steadfast dedication to cancer prevention and improved cancer care," said Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. "For more than 50 years, sanofi-aventis has worked to improve the lives of patients with cancer - not only through our strategic focus on the research and discovery of new therapeutic approaches in oncology, but also through our support and efforts to improve the health and wellness of our employees and their families."

To earn Gold Standard accreditation, an organization must establish programs to reduce cancer through: (1) discouraging tobacco use; (2) encouraging physical activity; (3) encouraging healthy diet and nutrition; (4) detecting cancer at its earliest stages; and (5) providing access to quality care and clinical trials. Programs established under the guidance of the CEO Roundtable on Cancer help reduce cancer mortality, and statistics show that the efforts recognized by the Gold Standard have a tangible impact on the cost of treating cancer, which totaled nearly $210 billion in 2005 in the U.S., according to the Centers for Disease Control and Prevention.

"Our Gold Standard certification acknowledges the commitment to health and wellness made by sanofi-aventis, as well as the specific programs developed with its own employees and family members in the U.S.," said William C. Weldon, chairman and chief executive officer of Johnson & Johnson, and chair of the CEO Roundtable on Cancer. "Through the leadership of global CEO Christopher Viehbacher, sanofi-aventis has demonstrated its unwavering dedication to fighting cancer - and we are pleased to welcome them into the ranks of this select group."

Sanofi-aventis's progressive health and cancer prevention efforts in the U.S. include tobacco-free campuses as of November 19th, 2009; free screening programs for skin and prostate cancer; mammogram scheduling assistance and distribution of breast self-exam cards; and CancerConnect, a new employee support program that provides employees with resources and support to help navigate the journey of their own or a loved one's cancer diagnosis. The company's recent donation of chemotherapy products to the Foundation for the National Institutes of Health for clinical trial use, its continued sponsorship of the cancer awareness initiative Kaleidoscope (formerly known as Frosted Pink) as well as many other cancer education and awareness programs further underscore this accreditation.

The Gold Standard accreditation puts sanofi-aventis in the company of the following organizations also recognized as championing workplace-based efforts to eliminate cancer as a public health threat: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, CIGNA, Dana-Farber Cancer Institute, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Millennium: The Takeda Oncology Company, Minot State University, H. Lee Moffitt Cancer Center and Research Institute, The National Cancer Institute (NCI), Novartis, The Oncology Nursing Society, OSI Pharmaceuticals, Pfizer, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota, US Oncology, Valeant Pharmaceuticals, Vanderbilt-Ingram Cancer Center, Virtua Health and The Wistar Institute.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard encouraging its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please visit www.CancerGoldStandard.org.

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, www.sanofi-aventis.com.

    Contact:
    Noelle Boyd
    sanofi-aventis U.S.
    908-981-6489


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sanofi-Aventis renews licenses for Genomatix chip analysis pipeline
2. Sanofi-aventis US Chairman Tim Rothwell Addresses CMSAs Collaborative Practice Summit
3. Sanofi-aventis Announces a Good Third Quarter Performance; Increase in 2007 full-year earnings growth guidance
4. Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
5. TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement
6. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
7. Sanofi-aventis Named One of Best Employers for Healthy Lifestyles by National Business Group on Health
8. Sanofi-aventis Teams With HHS Quality Agency to Distribute Consumer Health Materials
9. Sanofi-aventis Q3 2008 Adjusted EPS Excluding Selected Items(1):
10. Welvista Announces Partnering with sanofi-aventis U.S. to Provide Medication at No Cost to the Uninsured
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work ... as “patient engagement.” The patient is doing more than filling out a survey; in ... “There is an increasing emphasis in health care and research on the importance of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor ... prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017 The Rebound mobile app is poised ... reverse the tide of prescription drug addiction. The app empowers ... intake and stepping down their dosage in a safe, controlled ... December 2017; the first 100,000 people to sign up will ... http://www.rebound-solution.com/ ...
(Date:9/25/2017)... Sept. 25, 2017   Montrium , an ... solutions, today—from the IQPC Trial Master Files & ... NL)—announced that EastHORN Clinical Services has selected ... and TMF management. EastHORN, a leading European contract ... to increase transparency to enable greater collaboration with ...
(Date:9/19/2017)... ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device ... precise destruction of targeted tissues, announced three leadership team developments today:   ... Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology: